What are the real opportunities in value based pricing for drugs? x.com/ZSAssociates/s…

You thought prescription drug pricing was challenging? Gene therapies make it even harder. Read about it in my blog! lnkd.in/d2Wa54e lnkd.in/d2rGTYw

It’s disappointing to see that an HHS secretary with a #pharma background isn’t able to overcome the #Trump Twitter culture to seek real solutions. info.zs.com/priceofglobalh…

.ZS is seeking applicants for a Strategy Insights & Planning Consultant position within our Value & Access practice who will work with project leadership to define project scope. Apply to our Princeton office: bit.ly/2ACUbQh #ZSJobs

What should pharma companies be doing to succeed in today’s payer-empowered world? Here are two changes that they need to make. lnkd.in/dndBMZk

.ZS is seeking applicants for a Strategy Insights & Planning Consultant position within our Value & Access practice who will work with project leadership to define project scope. Apply: bit.ly/2ACUbQh #ZSJobs

ZS’s Healthcare Ecosystem team is currently looking to add a Strategy Insights & Planning Consultant to help clients tailor their commercial strategy to suit the complex IDN landscape. Learn more and apply to our San Francisco office: bit.ly/2lkcXG7 #ZSJobs

We’re behind the scenes at Managing Director Chris Wright’s annual video shoot! Every January, Chris invites ZSers around the world to tune in and watch him deliver the latest on ZS’s business, performance and strategy. #LifeAtZS

Understanding how patients, payers and providers make decisions can help #pharma companies design a winning value strategy. Here’s how: info.zs.com/priceofglobalh…

The inaugural #STATSummit centered on key topics around #drugpricing and #innovation. ZS’s Ed Schoonveld weighs in: bit.ly/35Krosh

It will be interesting to see how the cholesterol market further develops. lnkd.in/d8tHRSe

Is International Price Referencing stacking the deck? Read my recent article in the Pharmaceutical Executive. lnkd.in/d48Zvc9

Discussing market access industry trends with industry leaders. My colleague Dean and I wrote a blog about it. lnkd.in/etchmHj

Drug importation to deflect attention from impeachment. I guess it is better than starting a war. lnkd.in/dib5fGh

Drug cost is a challenge for some patients that needs addressing. However what about the burden to society of poor nutrition. An interesting recent study is an eye opener. Read my blog for a review. lnkd.in/duBAcpW

Interesting article from Matt Herper about the #drugpricing debate. lnkd.in/dp2SAfC

Read about the emerging co-pay accumulator programs in a blog from my colleague Howard Deutsch. Great reading. lnkd.in/ekARrwD

Will European Price Alliances change the drug pricing landscape? What does it mean for the pharma industry? lnkd.in/d3W_He6

Due to his visionary thinking and willingness to take risks, ZS Principal Jean-Jacques “JJ” Raoult was named one of Consulting Magazine’s #Top25Consultants of 2018: bit.ly/2KJ6tfk

Outcomes based contracting and value based pricing models offer great opportunities, but Pharma can do better... lnkd.in/ennhdiH lnkd.in/e4yXC52